Institute of Disaster and Emergency Medicine, Tianjin University, Tianjin 300072, China.
Tianjin Key Laboratory of Disaster Medicine Technology, Tianjin 300072, China.
Biomolecules. 2023 Nov 20;13(11):1674. doi: 10.3390/biom13111674.
The gut is the body's largest immune organ, and the intestinal barrier prevents harmful substances such as bacteria and toxins from passing through the gastrointestinal mucosa. Intestinal barrier dysfunction is closely associated with various diseases. However, there are currently no FDA-approved therapies targeting the intestinal epithelial barriers. Long noncoding RNAs (lncRNAs), a class of RNA transcripts with a length of more than 200 nucleotides and no coding capacity, are essential for the development and regulation of a variety of biological processes and diseases. lncRNAs are involved in the intestinal barrier function and homeostasis maintenance. This article reviews the emerging role of lncRNAs in the intestinal barrier and highlights the potential applications of lncRNAs in the treatment of various intestinal diseases by reviewing the literature on cells, animal models, and clinical patients. The aim is to explore potential lncRNAs involved in the intestinal barrier and provide new ideas for the diagnosis and treatment of intestinal barrier damage-associated diseases in the clinical setting.
肠道是人体最大的免疫器官，肠道屏障可以防止细菌和毒素等有害物质穿过胃肠道黏膜。肠道屏障功能障碍与各种疾病密切相关。然而，目前还没有 FDA 批准的针对肠道上皮屏障的治疗方法。长非编码 RNA（lncRNA）是一类长度超过 200 个核苷酸且没有编码能力的 RNA 转录本，对于多种生物过程和疾病的发生和调控至关重要。lncRNA 参与肠道屏障功能和稳态维持。本文通过回顾细胞、动物模型和临床患者的相关文献，综述了 lncRNA 在肠道屏障中的新兴作用，并强调了 lncRNA 在治疗各种肠道疾病中的潜在应用，旨在探索参与肠道屏障的潜在 lncRNA，为临床中肠道屏障损伤相关疾病的诊断和治疗提供新思路。
Zotero 插件